BUFORD, Ga.--(Business Wire)--
Theragenics Corporation (NYSE: TGX) expects to release third quarter 2009
consolidated financial results before the market opens on November 5, 2009.
Following this release, the Company will host a conference call at 11:00 a.m.
Eastern.
To participate in the call, dial 800-538-9844 or 706-634-7274 and provide the
conference ID 36213501. This call is also being webcast and can be accessed via
Theragenics` website, www.theragenics.com. A replay will be available on the
website for one month. A phone replay will be available until Midnight, November
12, by dialing 800-642-1687 or 706-645-9291 and entering the conference ID
36213501.
Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical
products business and its brachytherapy seed business. Its surgical products
business (www.cpmedical.com, www.galtmedical.com, www.needletech.com)
manufactures and distributes wound closure, vascular access, and specialty
needle products. Wound closure products include sutures, needles and other
surgical products. Vascular access includes introducers, guidewires and related
products. Specialty needles include coaxial, biopsy, spinal and disposable
veress needles, access trocars, and other needle based products. The surgical
products segment serves a number of markets and applications, including, among
others, interventional cardiology, interventional radiology, vascular surgery,
orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain
management, endoscopy, and spinal surgery. Theragenics` brachytherapy business
manufactures and markets its premier product, the palladium-103 TheraSeed®
device (www.theraseed.com) and I-Seed, an iodine-125 based device, which are
used primarily in the minimally invasive treatment of localized prostate
cancer.
Theragenics Corporation
Frank J. Tarallo, CFO & Treasurer
or
Lisa Rassel, Manager, Investor Relations
770-271-0233 or 800-998-8479
www.theragenics.com
Copyright Business Wire 2009
